Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) shot up 4.3% during trading on Monday . The company traded as high as $16.69 and last traded at $16.68. 573,639 shares traded hands during trading, a decline of 25% from the average session volume of 763,015 shares. The stock had previously closed at $15.99.
Analysts Set New Price Targets
A number of research firms have commented on SPRY. William Blair raised shares of ARS Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Leerink Partners upped their target price on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a report on Friday, September 20th. Finally, Raymond James upgraded ARS Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and upped their target price for the company from $18.00 to $22.00 in a report on Tuesday, August 13th. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $24.00.
Check Out Our Latest Stock Analysis on ARS Pharmaceuticals
ARS Pharmaceuticals Stock Up 4.6 %
The business has a fifty day moving average of $13.61 and a 200 day moving average of $10.82.
ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). The company had revenue of $0.50 million during the quarter, compared to analysts' expectations of $2.00 million. Analysts expect that ARS Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.
Insider Buying and Selling at ARS Pharmaceuticals
In other ARS Pharmaceuticals news, insider Eric Karas sold 10,000 shares of the stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the transaction, the insider now owns 5,693 shares in the company, valued at $79,702. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other ARS Pharmaceuticals news, insider Eric Karas sold 10,000 shares of the stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the transaction, the insider now owns 5,693 shares in the company, valued at $79,702. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Richard E. Lowenthal sold 100,000 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $12.93, for a total value of $1,293,000.00. Following the transaction, the chief executive officer now owns 1,398,499 shares in the company, valued at approximately $18,082,592.07. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,055,895 shares of company stock worth $14,619,032 over the last 90 days. Insiders own 40.10% of the company's stock.
Institutional Investors Weigh In On ARS Pharmaceuticals
Hedge funds have recently modified their holdings of the business. nVerses Capital LLC bought a new stake in shares of ARS Pharmaceuticals in the third quarter valued at approximately $30,000. Russell Investments Group Ltd. bought a new stake in shares of ARS Pharmaceuticals in the first quarter valued at approximately $60,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company's stock valued at $63,000 after acquiring an additional 4,472 shares during the period. Principal Financial Group Inc. bought a new stake in shares of ARS Pharmaceuticals in the second quarter valued at approximately $87,000. Finally, Paloma Partners Management Co bought a new stake in shares of ARS Pharmaceuticals in the first quarter valued at approximately $103,000. 68.16% of the stock is owned by institutional investors.
About ARS Pharmaceuticals
(
Get Free Report)
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
See Also
Before you consider ARS Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.
While ARS Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
